Fibroblast growth factor 21 (FGF21) is a hormone known for regulation of metabolic rate, energy expenditure and food consumption. Modification of this hormone is said to improve metabolic health and enhance weight loss in humans the rate of dosing required to achieve efficacy limits their therapeutic potential.
BFKB8488A is an antibody that mimics the effects of FGF21. A single subcutaneous injection of this antibody in a Phase 1a randomized, blinded, placebo-controlled clinical trial in 60 obese participants demonstrated the known long-lasting effects of the antibody and effectively reduced body weight when the participants received standard caloric meals during a confinement period of 6 days.
Weight loss in excess of 1.20 kg was recorded in the treatment group as opposed to a 0.28 kg decrease in the placebo group. A rebound in body weight was recorded within 3 days after confinement. A decrease in calorie consumption was observed to reach a maximum of 50% between days 15 and 22. More specifically was carbohydrate reduction and increased aversion to sweet foods.
The findings suggest that the antibody experimental drug may be safe for use and be very effective for obesity therapy and other related metabolic conditions.